Review
doi: 10.1016/0952-7915(91)90096-j.
Current applications of monoclonal antibodies for the therapy of hematopoietic cancers
Affiliations
- PMID: 1661602
- DOI: 10.1016/0952-7915(91)90096-j
Item in Clipboard
Review
Current applications of monoclonal antibodies for the therapy of hematopoietic cancers
Curr Opin Immunol.
1991 Oct.
Abstract
Recent trials of monoclonal antibodies in patients with leukemias or lymphomas have demonstrated the remarkable potency of these agents to kill tumor cells specifically and safely. New molecular biological and radiochemical techniques are also allowing rapid inroads into the remaining obstacles to this mode of therapy.
Similar articles
-
Monoclonal antibody therapy of lymphomas and leukemia.Cancer Treat Res. 1988;38:253-63. doi: 10.1007/978-1-4613-1713-5_8. Cancer Treat Res. 1988. PMID: 2908598 Review. No abstract available.
-
Biologicals for cancer treatment: monoclonal antibodies.Hosp Pract (Off Ed). 1985 Nov 15;20(11):67-74, 77, 80-4 passim. doi: 10.1080/21548331.1985.11703189. Hosp Pract (Off Ed). 1985. PMID: 3932392 Clinical Trial. No abstract available.
-
Antibodies in the treatment of lymphoma.Clin Oncol (R Coll Radiol). 2001;13(4):251-61. doi: 10.1053/clon.2001.9264. Clin Oncol (R Coll Radiol). 2001. PMID: 11554621 Review. No abstract available.
-
Treatment of lymphoid tumors with anti-idiotype antibodies.Springer Semin Immunopathol. 1983;6(1):99-115. doi: 10.1007/BF01857369. Springer Semin Immunopathol. 1983. PMID: 6351310 Review. No abstract available.
-
Monoclonal antibodies in the study and therapy of hematopoietic cancers.Curr Opin Immunol. 1992 Oct;4(5):641-6. doi: 10.1016/0952-7915(92)90040-l. Curr Opin Immunol. 1992. PMID: 1418732 Review.
Cited by
-
In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin.Eur J Nucl Med Mol Imaging. 2010 May;37(5):851-61. doi: 10.1007/s00259-009-1356-x. Epub 2010 Jan 27. Eur J Nucl Med Mol Imaging. 2010. PMID: 20107790
-
Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19.Cancer Immunol Immunother. 1995 Jan;40(1):37-47. doi: 10.1007/BF01517234. Cancer Immunol Immunother. 1995. PMID: 7530170 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
